Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2022

View Archived Issues

BCY-6033: EphA2-targeting BTC with efficacy in NSCLC PDX models

Enliven Therapeutics describes new Bcr-Abl kinase inhibitors

Silverback Therapeutics synthesizes TGFR-1 inhibitors and antibody-drug conjugates

CD38 inhibitors discovered at Napa Therapeutics, Buck Institute

Kymera Therapeutics presents STAT-degrading PROTACs

Vertex Pharmaceuticals patents CFTR modulators

Platform delivers siRNA targeting VEGF intravitreally for diabetic retinopathy

Turning Point and LaNova enter license agreement for LM-302 and collaboration on ADC programs

Insilico Medicine nominates preclinical candidate targeting MAT2A for MTAP-deleted cancers

Betta Pharmaceuticals presents preclinical results for cancer candidates BPI-371153 and BPI-442096

SPH-5030 demonstrates potent and selective activity in HER2-mutant cancer models

Orion enters agreement with Jemincare for Nav1.8 blocker for treatment of pain

Mosaic signs license agreement covering use of cowpea mosaic virus to treat cancer

Preclinical pipeline progress at Intellia Therapeutics

Clover reports neutralization findings from preclinical study of bivalent COVID-19 vaccine candidate

Taking aim at tumor metabolism, while taming toxicity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...